Status and phase
Conditions
Treatments
About
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Study participant must have a diagnosis of moderate to severe plaque psoriasis (PSO) for ≥3 months and:
>Clinically relevant facial or scalp involvement
>Clinically relevant genital involvement
>Clinically relevant palm and sole involvement
>Clinically relevant axillary involvement Study participants aged ≥12 years may alternatively have a diagnosis of moderate to severe mixed guttate/plaque PSO with >50 % to <80 % guttate lesions for ≥3 months, and must meet the same criteria listed above
Study participant must be a candidate for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
150 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
UCB Cares
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal